Susquehanna International Group, LLP Bio Xcel Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $527 Billion
- Q2 2024
A detailed history of Susquehanna International Group, LLP transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 173,318 shares of BTAI stock, worth $107,457. This represents 0.0% of its overall portfolio holdings.
Number of Shares
173,318
Previous 90,190
92.17%
Holding current value
$107,457
Previous $254,000
12.99%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BTAI
# of Institutions
68Shares Held
6.99MCall Options Held
101KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA1.2MShares$744,8530.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$273,2240.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$184,7860.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$114,7350.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$80,5180.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $17.4M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...